U.S. markets open in 8 hours 23 minutes
  • S&P Futures

    3,694.75
    +24.75 (+0.67%)
     
  • Dow Futures

    29,523.00
    +180.00 (+0.61%)
     
  • Nasdaq Futures

    11,396.50
    +80.25 (+0.71%)
     
  • Russell 2000 Futures

    1,678.70
    +16.20 (+0.97%)
     
  • Crude Oil

    77.20
    +0.49 (+0.64%)
     
  • Gold

    1,638.70
    +5.30 (+0.32%)
     
  • Silver

    18.50
    +0.02 (+0.11%)
     
  • EUR/USD

    0.9640
    +0.0029 (+0.30%)
     
  • 10-Yr Bond

    3.8780
    0.0000 (0.00%)
     
  • Vix

    32.26
    +2.34 (+7.82%)
     
  • GBP/USD

    1.0773
    +0.0090 (+0.84%)
     
  • USD/JPY

    144.5390
    -0.1410 (-0.10%)
     
  • BTC-USD

    20,057.14
    +1,229.82 (+6.53%)
     
  • CMC Crypto 200

    459.02
    +25.92 (+5.98%)
     
  • FTSE 100

    7,020.95
    +2.35 (+0.03%)
     
  • Nikkei 225

    26,566.21
    +134.66 (+0.51%)
     

GSK (GSK) Gains But Lags Market: What You Should Know

·3 min read

GSK (GSK) closed at $31.51 in the latest trading session, marking a +0.06% move from the prior day. The stock lagged the S&P 500's daily gain of 0.66%. At the same time, the Dow added 0.61%, and the tech-heavy Nasdaq gained 0.08%.

Coming into today, shares of the drug developer had lost 17.78% in the past month. In that same time, the Medical sector lost 4.7%, while the S&P 500 lost 3.79%.

Investors will be hoping for strength from GSK as it approaches its next earnings release. In that report, analysts expect GSK to post earnings of $1.20 per share. This would mark a year-over-year decline of 4.76%. Meanwhile, our latest consensus estimate is calling for revenue of $8.78 billion, down 29.84% from the prior-year quarter.

For the full year, our Zacks Consensus Estimates are projecting earnings of $3.37 per share and revenue of $34.61 billion, which would represent changes of -13.37% and -26.2%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for GSK. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 1.84% lower. GSK is holding a Zacks Rank of #4 (Sell) right now.

Valuation is also important, so investors should note that GSK has a Forward P/E ratio of 9.34 right now. This represents a discount compared to its industry's average Forward P/E of 20.12.

Also, we should mention that GSK has a PEG ratio of 1.15. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. GSK's industry had an average PEG ratio of 1.39 as of yesterday's close.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 73, which puts it in the top 29% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research